Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

2.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Five new papers highlight cancer inequities, challenges and opportunities in South Asia

5.

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot